Pharmacokinetic and safety data from healthy volunteers anticipated in the second half of 2025 On track to initiate a proof-of-concept study in psoriasis in the second half of 2025, with initial...
MENLO PARK, Calif., Dec. 18, 2024 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. (“Oruka”) (Nasdaq: ORKA), a biotechnology company developing novel biologics designed to set a new standard for the...
MENLO PARK, Calif., Nov. 19, 2024 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. (“Oruka”) (Nasdaq: ORKA), a biotechnology company developing novel biologics designed to set a new standard for the...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.54 | -2.49192431934 | 21.67 | 21.67 | 19.8375 | 907259 | 20.48665678 | CS |
4 | 0.45 | 2.17601547389 | 20.68 | 25.65 | 19.76 | 419773 | 21.38774523 | CS |
12 | -3.9 | -15.5813024371 | 25.03 | 31.13 | 18.2 | 231942 | 23.01034466 | CS |
26 | -7.87 | -27.1379310345 | 29 | 31.13 | 18.2 | 184804 | 23.16356581 | CS |
52 | -7.87 | -27.1379310345 | 29 | 31.13 | 18.2 | 184804 | 23.16356581 | CS |
156 | -7.87 | -27.1379310345 | 29 | 31.13 | 18.2 | 184804 | 23.16356581 | CS |
260 | -7.87 | -27.1379310345 | 29 | 31.13 | 18.2 | 184804 | 23.16356581 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.